Quick Takeaways:
- Loyal announced that the FDA Center for Veterinary Medicine has accepted the Target Animal Safety (TAS) section for LOY-002, its lead lifespan-extension drug for senior dogs, marking 2 of 3 key sections (TAS + RXE) now cleared toward potential market entry.
- A daily prescription pill, LOY-002 is designed to extend a healthy lifespan by targeting metabolic drivers of aging and delaying disease onset, potentially becoming the first FDA-approved longevity drug in any species. The TAS package included data from 400+ dogs in the pivotal STAY trial, with the FDA confirming its safety under proposed use.
- With prior RXE acceptance (Feb’25) and full enrollment of the 1,300-dog STAY study, the largest in veterinary history. Loyal is now preparing the final section for Expanded Conditional Approval (XCA), aiming to bring the first canine longevity therapy to market as early as next year.
Why It Matters?
With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market.
If LOY-002 reaches conditional approval, senior-dog care could shift from managing late-stage disease to proactively modifying aging itself, creating a new chronic “longevity” category alongside diets, supplements, and preventive meds.
Source: Businesswire
